Protamine Modulates CSPG-RPTPσ Binding for Neural Regeneration

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for central nervous system injuries, such as traumatic brain and spinal cord injuries, are inadequate as they fail to promote effective regeneration due to the inhibitory effects of chondroitin sulfate proteoglycans (CSPGs), which prevent axon and dendrite growth, and existing neuroprotective strategies have shown limited efficacy in clinical trials.

Innovation Solution

The use of protamine or its peptides to modulate the CSPG matrix by increasing its binding to the receptor RPTPσ, thereby converting an inhibitory environment into a permissive one for neurite outgrowth and neural regeneration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chondroitin sulfate proteoglycans (CSPGs) are present in the glial scar, then the scar forms to protect the injury site, but axon and dendrite growth is inhibited

Engineering Contradiction:
Improveprotection of injury siteVSAvoidinhibition of neurite outgrowth
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies this principle by using protamine to convert the harmful inhibitory effect of CSPGs into a beneficial outcome. Protamine binds to CSPGs and modulates their interaction with RPTPσ receptors, transforming the glial scar from a barrier that blocks regeneration into a permissive environment that supports neurite outgrowth and neural regeneration while maintaining the protective function of the scar.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent uses protamine as an intermediary substance that mediates between CSPGs and RPTPσ receptors. Protamine binds to CSPGs and modifies their interaction with neuronal receptors, acting as a molecular bridge that converts the inhibitory signal into a permissive signal for neural regeneration without removing the CSPGs or the glial scar structure.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If neuroprotective treatments are administered, then some protection is provided, but effective regeneration is not promoted due to CSPG inhibition

Engineering Contradiction:
ImproveneuroprotectionVSAvoidregeneration rate
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent applies parameter changes by modifying the biochemical interaction parameters between CSPGs and neuronal receptors through protamine binding. This changes the functional state of the CSPG matrix from inhibitory to permissive, enabling both neuroprotection and active regeneration to occur simultaneously by altering the molecular recognition parameters at the injury site.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Protamine and its peptides promote CNS regeneration by enhancing CSPG binding to RPTPσ, facilitating axon and dendrite growth, and have been shown to improve functional recovery in animal models of spinal cord injury, demonstrating potential as a novel therapeutic approach for central nervous system injuries.

Implementation Method 1

protamine increases the interaction of chondroitin sulphate proteoglycan (CSPG) to the receptor protein tyrosine phosphatase sigma (RPTPσ)

Methodology Applied
Scientific EffectBinding interaction: Adsorption

Data Source

PatentEP3010524B1Protamine in treatment of neuronal injuries
Publication Date: 2019.12.25 UNIVERSITY OF HELSINKI
  • EP3010524B1 patent drawingFigure 1~2
  • EP3010524B1 patent drawingFigure 3A
  • EP3010524B1 patent drawingFigure 3B

AI summary

The present invention relates to treatment of neuronal injury. The present invention discloses a novel use of an agent and a novel method for promoting neurite out growth and/or neural regeneration in CNS injuries. A novel mechanism of promoting neurite outgrowth by increasing the interaction of chondroitin sulphate proteoglycan (CSPG) to receptor protein tyrosine phosphatase sigma (RPTPσ) is disclosed.